Clinical Scorecard: Semaglutide Tied to Aging Clocks in HIV
At a Glance
| Category | Detail |
|---|---|
| Condition | HIV-associated lipohypertrophy |
| Key Mechanisms | Slower epigenetic aging associated with semaglutide treatment |
| Target Population | Patients with HIV-1 infection, stable antiretroviral therapy, and clinical evidence of lipohypertrophy |
| Care Setting | Single-center, phase 2b randomized, double-blind, placebo-controlled trial |
Key Highlights
- Semaglutide associated with lower annualized epigenetic aging estimates compared to placebo
- Largest differences observed in PhenoAge, SystemsAge, and PCGrimAge
- 9% slower pace of aging measured by DunedinPACE
- System-specific epigenetic measures favored semaglutide for several aging estimates
- Findings are exploratory and require further prospective trials
Guideline-Based Recommendations
Diagnosis
- Patients must have documented HIV-1 infection and clinical evidence of lipohypertrophy
Management
- Semaglutide titrated from 0.25 mg to 1.0 mg once weekly
Monitoring & Follow-up
- Assess epigenetic aging biomarkers at baseline and week 32
Risks
- Exclusion of patients with diabetes or active cardiovascular disease
Patient & Prescribing Data
84 patients with HIV-associated lipohypertrophy
Semaglutide showed significant effects on epigenetic aging biomarkers
Clinical Best Practices
- Consider patient eligibility criteria carefully
- Monitor for changes in epigenetic biomarkers during treatment
- Acknowledge the exploratory nature of findings
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
